Latest Information Update: 15 Oct 2002
At a glance
- Originator CeNeS Pharmaceuticals
- Class Antiparkinsonians; Neuroprotectants; Nootropics
- Mechanism of Action Glutamate receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neuroprotection
Most Recent Events
- 15 Oct 2002 Discontinued for Neuroprotection in USA (unspecified route)
- 30 May 2001 Profile reviewed but no significant changes made
- 06 Dec 1996 No-Development-Reported for Neuroprotection in USA (Unknown route)